Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18305611 | 0.83 | ALDH1A1 (0.35) | ALDH1A1KDM4EHPGDGAATRPV4 | |
| SCHEMBL25317647 | 0.79 | TRPV4 (0.33) | ALDH1A1KDM4EHPGDGAATRPV4 | |
| SCHEMBL25430712 | 0.77 | IRAK4 (0.31) | — | |
| SCHEMBL25318072 | 0.74 | ALDH1A1 (0.37) | ALDH1A1KDM4EHPGDFFAR4GAA | |
| SCHEMBL2429750 | 0.74 | FFAR4 (0.34) | ALDH1A1FFAR4GAA | |
| SCHEMBL30439195 | 0.73 | HTR2A (0.33) | TRPV4 | |
| SCHEMBL25045830 | 0.73 | HTR2A (0.33) | TRPV4 | |
| SCHEMBL29054638 | 0.73 | MAOA (0.38) | ALDH1A1KDM4ETRPV4 | |
| SCHEMBL30507823 | 0.71 | PDE4A (0.33) | TRPV4 | |
| SCHEMBL25564726 | 0.71 | PDE4A (0.33) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059204-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-02-20 | — | — | US | disclosed |
| EP-4448109-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | Aurigene Oncology Limited (IN) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023114710-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114710-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059204-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | ALDH1A1 1811/4885KDM4E 506/4885HPGD 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.